Companies: 10,795·Total market cap: $144.5T
Collegium Pharmaceutical, Inc.

Collegium Pharmaceutical, Inc.

COLLNASDAQHealthcare● Active
$33.56
+$0.18(+0.54%)
Market Cap$1.1B
P/E Ratio
52W High$50.787
52W Low$29.08
Overview

Collegium Pharmaceutical, Inc.(COLL)股票概览

关键指标与盈利、估值、营收、股息等标签页深链。

FMP · COLL · 截至 Jun 8, 2026

关键指标

EPS (TTM)coll eps ttm · coll earnings per shareEarnings history
PE Ratio (TTM)coll pe ratio ttm · coll price to earningsPE Ratio deep dive
Revenue (TTM)coll revenue ttm · coll annual revenueFull revenue history
Dividend Yield不分红does coll pay dividends · coll dividend yieldDividend history
Shares Outstandingcoll shares outstanding · coll floatShares outstanding history
Next EarningsTBAcoll earnings date · coll next earningsEarnings history

分析师评级与目标价

完整预测
SellBuy
Buy12 位分析师is coll a buy · coll analyst rating
Strong Buy
0
Buy
8
Hold
3
Sell
1
Strong Sell
0
12-Month Price Target
$56.00Low
$33.56Current
$58.00Avg Target上涨空间 72.82%
$60.00High
coll price target · coll 12 month forecast

合计: 12 · 买入占比: 66.7%

根据过去 3 个月内 12 位华尔街分析师,COLL 共识评级为 Buy,12 个月平均目标价 $58.00 (较现价 $33.56 上涨空间 72.82%)

关于 Collegium Pharmaceutical, Inc.

CEOVikram Karnani
IPO DateMay 7, 2015
Employees357
CountryUS

Collegium Pharmaceutical, Inc. a specialty pharmaceutical company, develops and commercializes medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, …

what is collegium pharmaceutical, inc. · coll stock overview · collegium pharmaceutical, inc. company profile · who is collegium pharmaceutical, inc. ceo · coll NASDAQ · collegium pharmaceutical, inc. headquarters · collegium pharmaceutical, inc. business segments

关于股票概览与关键数据

Collegium Pharmaceutical, Inc.(COLL)是 Drug Manufacturers - Specialty & Generic 行业的 Healthcare 类公司,于 May 7, 2015 在 NASDAQ 上市。截至最近交易日,COLL 股价为 $33.56,市值约为 $1.1B。过去12个月累计回报 —,年初至今回报 —。

常见问题

截至最近一个交易日,Collegium Pharmaceutical, Inc.(COLL)股价为 $33.56,在 NASDAQ 上市,52周区间为 $29.08 – $50.79。

COLL 最新股价COLL quote todaylive ticker 实时行情
数据来源:Financial Modeling Prep最后更新:Jun 8, 2026本内容不构成投资建议